400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Protein Tyrosine Kinase/RTK / VEGFR / 仑伐替尼甲酸盐
CAS No.: 857890-39-2
Synonyms: E7080 mesylate;Lenvatinib (mesylate);E-7080
Lenvatinib mesylate is an inhibitor of VEGFR2 with potential antineoplastic activity. It can decrease vascular endothelial cell migration and proliferation.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT03663114 | - | - | Recruiting | May 2021 | Japan ... more >> Eisai trial site 1 Recruiting Osaka, Japan Eisai trial site 2 Recruiting Tokyo, Japan Collapse << |
NCT03477175 | Solid Tumors | Phase 2 | Not yet recruiting | March 2028 | - |
NCT02430714 | - | - | Recruiting | March 1, 2025 | Japan ... more >> Recruiting Osaka, Japan Recruiting Tokyo, Japan Collapse << |
实验方案
技术信息
CAS号 | 857890-39-2 | 储存条件 |
|
|||||
分子式 | C22H23ClN4O7S | 运输 | 蓝冰 | |||||
分子量 | 522.96 | 别名 | E7080 mesylate;Lenvatinib (mesylate);E-7080;ER-203492-00;Lenvatinib;trade name Lenvima;仑伐替尼甲酸盐 | |||||
溶解度 |
|
动物实验配方 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT03663114 | - | - | Recruiting | May 2021 | Japan ... more >> Eisai trial site 1 Recruiting Osaka, Japan Eisai trial site 2 Recruiting Tokyo, Japan Collapse << |
NCT03477175 | Solid Tumors | Phase 2 | Not yet recruiting | March 2028 | - |
NCT02430714 | - | - | Recruiting | March 1, 2025 | Japan ... more >> Recruiting Osaka, Japan Recruiting Tokyo, Japan Collapse << |
NCT02973997 | Columnar Cell Variant Thyroid ... more >>Gland Papillary Carcinoma Follicular Variant Thyroid Gland Papillary Carcinoma Poorly Differentiated Thyroid Gland Carcinoma Recurrent Thyroid Gland Carcinoma Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 Stage III Thyroid Gland Follicular Carcinoma AJCC v7 Stage III Thyroid Gland Papillary Carcinoma AJCC v7 Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7 Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7 Tall Cell Variant Thyroid Gland Papillary Carcinoma Thyroid Gland Oncocytic Follicular Carcinoma Collapse << | Phase 2 | Recruiting | September 30, 2022 | United States, California ... more >> UC San Diego Moores Cancer Center Not yet recruiting La Jolla, California, United States, 92093 Contact: Kristina Laws 858-657-5283 kelaws@ucsd.edu Principal Investigator: Gregory A. Daniels Stanford Cancer Institute Palo Alto Not yet recruiting Palo Alto, California, United States, 94304 Contact: Michelle Jun dmjun@stanford.edu Principal Investigator: Alexander D. Colevas Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Recruiting Torrance, California, United States, 90502 Contact: Emily Ong 310-222-8172 emily.ong@labiomed.org Principal Investigator: Andrew G. Gianoukakis United States, Colorado University of Colorado Hospital Recruiting Aurora, Colorado, United States, 80045 Contact: Paula Fisk 720-848-0676 paula.fisk@ucdenver.edu Principal Investigator: Daniel W. Bowles United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Lori J. Wirth 617-724-6000 lwirth@mgh.harvard.edu Principal Investigator: Lori J. Wirth United States, Michigan University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Gregory W. Campbell 734-647-9075 gwcampbe@med.umich.edu Principal Investigator: Francis P. Worden United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Hisham Elsayed 646-888-5334 elsayedh@mskcc.org Principal Investigator: Eric J. Sherman United States, Ohio Ohio State University Comprehensive Cancer Center Not yet recruiting Columbus, Ohio, United States, 43210 Contact: Nicholas Bruno 614-688-7658 Nicholas.Bruno@osumc.edu Principal Investigator: Bhavana Konda United States, Tennessee Vanderbilt University/Ingram Cancer Center Not yet recruiting Nashville, Tennessee, United States, 37232 Contact: Rebecca Abel 615-343-7602 rebecca.abel@vumc.org Principal Investigator: Jill Gilbert United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Danielle Litofsky 713-794-1472 Dgutterm@mdanderson.org Principal Investigator: Ramona Dadu Collapse << |
NCT02788708 | Fallopian Tube Carcinoma ... more >> Recurrent Ovarian Cancer Primary Peritoneal Carcinoma Recurrent Endometrial Cancer Collapse << | Phase 1 | Recruiting | November 30, 2019 | United States, Ohio ... more >> Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Floor J. Backes, MD 614-293-7642 Floor.backes@osumc.edu Principal Investigator: Floor J. Backes, MD Collapse << |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网